Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Verinurad+Febuxostat · 1 trial · 3 indications
LS Mean Percentage Change (95% CI) from Baseline in UACR
LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo
| Arm | Type | Description |
|---|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | EXPERIMENTAL | Capsule administered orally, once daily for 24 weeks |
| Placebo | PLACEBO_COMPARATOR | Capsule administered orally, once daily for 24 weeks |
| Name | Type | Description |
|---|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | DRUG | Capsule administered orally, once daily for 24 weeks |
| Placebo | DRUG | Capsule administered orally, once daily for 24 weeks |
Inclusion Criteria: * Serum Uric Acid ≥6.0 mg/dL * eGFR ≥30 mL/min/1.73 m2 * UACR between 30 mg/g and 3500 mg/g inclusive * Diagnosed with T2DM Exclusion Criteria: * Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs for hyperuricemia include all XO inhibitors (...
Verinurad is an investigational small molecule being studied for chronic kidney disease, hyperuricemia, asymptomatic hyperuricemia, and heart failure with preserved ejection fraction (HFpEF). It has been evaluated in Phase 2 clinical trials for these conditions, though it remains investigational and is not approved.
Verinurad is a uric acid lowering agent. It has been studied in combination with febuxostat and dapagliflozin to assess its effect on urinary excretion of uric acid in patients with asymptomatic hyperuricemia. Its mechanism involves reducing uric acid levels.
Verinurad is being developed by AstraZeneca PLC, which is listed on the stock exchange under the ticker AZN. The company has sponsored clinical trials of Verinurad across multiple countries, including the United States and Germany.
Verinurad has completed Phase 2 clinical trials for hyperuricemia, asymptomatic hyperuricemia, and heart failure with preserved ejection fraction. It has also completed a Phase 1 trial in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
Verinurad has been studied in several completed trials. NCT03118739 evaluated it with febuxostat in patients with hyperuricemia and albuminuria. NCT03316131 assessed its effect on uric acid excretion with febuxostat and dapagliflozin. NCT04256629 examined its effect on heart electrical activity in healthy volunteers, and NCT04327024 studied it in heart failure with preserved ejection fraction.
Verinurad is also known as RDEA3170. In clinical trial NCT03316131, the study title refers to RDEA3170, which is the same drug as Verinurad. This alternative name may appear in older or related research documentation.